Entities

Advisory Board Member at Plaisance Capital Management and molecular biologist known for research into RNA-binding proteins, alternative splicing and regulation of gene expression.

Advisory Board Member at Plaisance Capital Management and chemist whose research focuses on RNA modifications and gene regulation.

Scientific adviser to Plaisance Capital Management and bioinformatician with research experience in epigenetics, RNA biology and genomic technologies.

Stellaromics co-founder and chief scientific officer. Previously a Plaisance Capital Management principal; RNA-modification researcher and biotechnology company builder. His current scientific role supersedes the CTO title in the2023announcement.

Venture Partner at Plaisance Capital Management and technology entrepreneur associated with Everex and eMachines. Team page calls him Lap Chun (John) Hui; biography also uses Lap Shun Hui.

Venture Partner and co-founder of Plaisance Capital Management, with experience in biotechnology investing and entrepreneurship. Previously co-founded Coalescence Partners; also called Frederic or Frederick Jiang.

Principal and Director of Operations at Plaisance Capital Management. Chemist with research experience in cancer therapeutics and epigenomic biomarkers; joined the firm in 2023.

Office Manager at Plaisance Capital Management, with experience in international business, investor relations and Chinese-English translation.

Investment Associate at Plaisance Capital Management, with oncology laboratory experience and a University of Chicago degree in English and clinical research.

Principal at Plaisance Capital Management with drug discovery and business development experience. Previously worked at WuXi AppTec; trained in regenerative medicine and nerve repair.

Corporate Counsel at Plaisance Capital Management; the individual biography also calls him General Counsel. Provides legal oversight for due diligence, transactions and portfolio management; Brooklyn Law School JD.

Principal at Plaisance Capital Management, working on investment strategy, due diligence, financial modelling, deal execution and portfolio support. Also named Yunxi Li; joined in September 2023.

Plaisance Capital Management is a Cambridge, Massachusetts-based biotechnology investment manager established in 2020. It provides venture investment, incubation and scientific guidance to healthcare startups. Its portfolio includes neuroscience drug developer Reunion Neuroscience, AI medical-imaging company Subtle Medical, medical-device businesses and biotechnology companies. The published team combines investment and operations professionals, venture partners, scientific advisers and an advisory board. Its legal name is Plaisance Capital Management, LLC. It is distinct from the similarly named public-markets manager Plaisance Capital at plaisancecapital.com. Fund sizes and investment ticket amounts have not been disclosed in the reviewed company sources.

Operates a recruiting and career platform for electricians and other skilled electrical and energy technicians. Workers use WhatsApp conversations to share experience, qualifications and job preferences; employers receive matched candidate profiles. The company combines an online technician community with recruitment services and is developing training and other tools for skilled technical careers.

Develops an AI infection-intelligence platform for hospitals. It combines clinical, microbiology and patient-contact data to help infection-control teams identify possible cases, investigate transmission clusters and predict where infection risks may emerge. The software supports surveillance and targeted prevention workflows, with technology developed from research at Imperial College London.

Develops an AI platform for managing external workforces, including contractors, freelancers and suppliers. Its software coordinates work requests, classification, sourcing, screening, onboarding, compliance and payments through AI-assisted workflows. The Munich-based company is also building tools for governing work performed by AI agents.

Develops blood-based glycan biomarker tests for assessing biological age and chronic inflammation. Its technology analyzes sugar structures attached to immunoglobulin G proteins and translates the results into reports for individuals, clinicians and researchers. The company is expanding clinical validation and diagnostic applications for preventive healthcare.

Develops a remote cardiac-monitoring system that combines a wearable chest-strap ECG sensor, a mobile app and AI-assisted rhythm analysis. Its platform supports long-term monitoring during daily life and gives clinicians access to recordings for reviewing arrhythmias and other heart-rhythm abnormalities.

Develops CoLumbo, AI software that assists radiologists in analyzing lumbar-spine MRI scans. The system segments anatomical structures, performs measurements, identifies relevant findings and helps generate structured reports, supporting diagnostic workflows for spine disease.

FemHealth Ventures is a Short Hills, New Jersey venture capital firm investing in women’s health across drugs, medical devices, diagnostics and digital or AI-enabled technologies. Its framework covers conditions occurring only in women, mostly in women or differently in women. Relevant investments include Reunion Neuroscience’s investigational postpartum depression treatment, Cercle’s AI-based health data platform and Mendaera’s medical robotics. The firm pairs investment professionals with an advisory board spanning biotechnology, healthcare investing, medicine and business. It reported a USD32 million debut fund closing in 2023 and announced a USD65 million Fund II closing in December 2025, reporting USD100 million of aggregate assets under management across two funds. Aggregate AUM is separate from individual disclosed closing amounts.

Early-stage venture capital firm backing technology founders from Southeastern Europe and its diaspora. Focuses on future-of-work software, digital health and fintech, including AI-driven businesses, and helps portfolio companies expand into Western European and US markets. Its partners combine company-building, enterprise technology and investment experience.

Early-stage venture capital firm backing technology founders in Central and Eastern Europe, Southeastern Europe and their diaspora. Leads pre-seed and seed rounds, typically investing EUR300,000 to EUR3 million, with reserves for follow-on funding. Its generalist strategy includes AI applications and infrastructure, enterprise software, robotics, industrial technology and other deep-tech businesses. Its team operates from Sofia, Zagreb and Cluj.

Provides an independent fact-checking API for teams publishing AI-generated text, reports and recommendations. Its verification pipeline researches public sources, compares arguments from multiple AI models and reviews the evidence to return claim verdicts, citations and an audit trail. It also checks draft documents and whether cited sources support their attributed claims, with integrations for AI assistants and automated workflows.

Develops AI-native management software for gyms, fitness studios and sports clubs. Its platform combines membership management, scheduling, billing and payments, marketing, websites and member engagement, with conversational AI reporting and workflow automation. Its sports network helps people discover activities and book sessions with participating clubs.

Alto adviser, Stanford psychiatry professor and director of the Stanford Mood Disorders Center. Previously chaired Stanford’s psychiatry department and served as president of several psychiatric professional societies. He is a National Academy of Medicine member and trained at Harvard and NYU.

Charles Nemeroff serves as Scientific and Medical Advisor at Engrail Therapeutics, a precision neuroscience drug-development company.

Dr. Natalie Sacks joined Venture Investments in 2022 as a Venture Partner based in the San Francisco office. Dr. Sacks is an oncologist and drug developer with over 20 years of experience in the biotechnology industry.  Prior to joining Venture Investments, she served as the Chief Medical Officer at Harpoon Therapeutics. Prior to that, she held various development and executive leadership roles at multiple companies including at Onyx Pharmaceuticals (acquired by Amgen), Aduro, Exelixis, and Cell Genesys. She has been responsible for all aspects of development ranging from initial IND to the late-stage development of commercially available oncology therapeutics. Dr. Sacks held a faculty appointment at the University of California, San Francisco for more than ten years, where she was a volunteer assistant clinical professor of medicine in the Division of Hematology/Oncology. She received her B.A. in Mathematics from Bryn Mawr College, her M.S. in Biostatistics from the Harvard University School of Public Health, and her M.D. from the University of Pennsylvania School of Medicine.

Managing partner responsible for both Arkin Bio Ventures and Arkin Bio Capital. Combines biotechnology investing with drug-development experience; joined Arkin in 2010.

Biopharmaceutical adviser to Two Bear Capital and Reunion Neuroscience board member, with former business leadership roles at Werewolf Therapeutics and Impel NeuroPharma.

Reunion Neuroscience is a Morristown, New Jersey clinical-stage biotechnology company developing psychedelic-inspired treatments for mental health disorders. Its lead investigational drug, luvesilocin (formerly RE104), is a patented prodrug of 4-OH-DiPT that targets the serotonin 2A receptor and is designed for subcutaneous administration with a shorter acute psychedelic experience. The company is studying postpartum depression, adjustment disorder and generalized anxiety disorder. It reported positive Phase 2 postpartum depression results and received FDA Breakthrough Therapy Designation in February 2026; the drug remains investigational. Reunion became privately held after its acquisition by an MPM BioImpact affiliate in 2023. Its Series A financing, initially announced at USD103 million in May 2024, reached USD133 million at the final tranche closing in September 2025. Sahil Kirpekar became President and CEO in June 2026.

Scientific adviser to BEVC; Stanford chemist and Nobel laureate in bioorthogonal chemistry. Carolyn R. Bertozzi returned to Lilly’s board in 2025 after earlier service during 2017–2021. She leads Stanford’s Sarafan ChEM-H and is a chemistry professor and Howard Hughes investigator. She studied chemistry at Harvard and Berkeley and developed foundational work in bioorthogonal chemistry.

MPM BioImpact is a Boston-based biotechnology investment firm that builds and finances drug development companies across private and public markets. It combines MPM Capital’s biotechnology venture investing with BioImpact’s public-market and impact investing, managing more than USD3 billion across early-stage venture funds, private/public impact funds and a public equities fund. Its investment professionals and entrepreneur partners provide scientific expertise, company formation and drug development leadership. Neuroscience investments include Arialys Therapeutics, AstronauTx and Reunion Neuroscience. The current website is published by MPM BioImpact LLC; MPM Capital and other affiliated legal entities and historical funds retain distinct identities. Aggregate assets under management are not the capital of a single fund.

Independent director of Immunic. Pharmaceutical executive with experience at Mineralys, Impel NeuroPharma, Nivalis and Teva, including commercial leadership in multiple sclerosis and neuroscience. Also an operating partner at Catalys Pacific.

Catalys Pacific is an independent life-sciences venture capital firm and company builder operating across Japan and the United States. Catalys Pacific, LLC was established in 2018 and publicly launched its first fund inJune 2019. The firm combines local sourcing, scientific expertise and transpacific partnerships to form and finance biotechnology companies: advancing Japanese discoveries into global development and bringing overseas therapies into development and commercialization in Japan. Its activities include neuroscience and neuropsychiatry through creations such as Arialys, Aculys and Transposon. The firm is independently governed; its pharmaceutical strategic partners are limited partners, not a parent pharmaceutical company. Named vehicles include Catalys Pacific Fund, LP, Fund II and a Post-POC Fund for follow-on investment in clinical proof-of-concept companies. Its public roster includes investment professionals, operating partners and advisers.

Avalon BioVentures is a San Diego biotechnology venture investor and company builder focused on first-in-class therapeutics and early scientific opportunities, including neurodegenerative diseases. Its ABV Accelerator provides laboratory space in La Jolla’s Torrey Pines research area, scientific leadership, operating executives and shared finance, HR and other business services to young biotechnology companies. The life-science-focused firm emerged from Avalon Ventures, whose earlier funds also invested in technology; these are distinct organizations and historical Avalon portfolio companies are not automatically investments of the newer ABV I fund. Avalon BioVentures announced the close of its first dedicated biotech fund, ABV I, at USD135 million on December 6, 2022. It co-founded Arialys Therapeutics and participated in its USD58 million September 2023 seed financing.

Develops oral medicines targeting abnormal retrotransposon activity and other pathways involved in neurodegenerative and aging-related diseases. Its lead investigational drug, TPN-101, inhibits LINE-1 reverse transcriptase and is being developed for ALS, progressive supranuclear palsy and Alzheimer’s disease. The pipeline also includes nucleoside analogs and PKR inhibitors.

Adam Boxer is listed by Vesper Bio as Scientific Advisor. UCSF neurologist and clinical researcher in frontotemporal dementia and neurodegenerative-disease therapeutics; current Vesper scientific-advisory affiliation is separate from existing roles.

Maurizio Fava serves as Scientific Advisory Board Member at Newleos Therapeutics, a clinical-stage neuroscience company. Maurizio Fava MD is a published external PureTech collaborator and executive vice chair of psychiatry and director of the clinical trials network and institute at Massachusetts General Hospital. His existing Newleos scientific advisory identity and portrait are preserved.

Life-sciences investor with research experience and a biology PhD from the Max Planck Society; biotechnology degrees from IIT Madras.

Develops small-molecule medicines for cognitive impairment associated with Alzheimer’s disease, depression, schizophrenia and other brain disorders. Its lead investigational drug, DPX-101, selectively enhances α5-GABA-A receptor activity to support neuronal signaling and connections. The program has FDA clearance for Phase 1 clinical testing; cognitive benefits described so far come from preclinical studies.

Brock Reeve was named by Bioverge’s own 2023 Republic corporate offering as External Advisor. The campaign explicitly includes people helping build Bioverge beyond employees. This establishes a dated platform affiliation, with current tenure, formal employment and any personal investment not inferred.

Clifford Woolf co-founded QurAlis and serves on its scientific advisory board. His research spans neural mechanisms of pain, neurodegeneration and patient-derived stem-cell disease models; his career includes University College London, Harvard and Boston Children’s Hospital after medical and doctoral training at the University of the Witwatersrand.

Raymond J. Kelleher is managing director of Cormorant Asset Management, a position its current roster confirms and a 2026 issuer proxy dates to July 2020. He practices neurology at Massachusetts General Hospital with a focus on Alzheimer’s disease and related dementias. He trained at MIT and Stanford, earning an MD and PhD. The issuer dates his Harvard assistant professorship from July 2005 to October 2023; it is a former appointment. His investment and clinical roles are distinct from personal cash investments.

Myrobalan scientific co-founder and board adviser, and a Harvard Medical School professor of neurology and ophthalmology. Studies axon regeneration, neurodegeneration and remyelination. Holds a University of Toronto PhD and completed postdoctoral research at UCSF. Also a scientific adviser to Axonis Therapeutics.

Develops selective SGK1 inhibitors for inherited heart-rhythm disorders, heart failure and neurodegenerative disease. Its lead oral drug candidate, THRV-1268, is in clinical development for Long QT Syndrome. A separate licensed chemistry program is being developed for brain-penetrant compounds targeting Parkinson’s disease, Alzheimer’s disease and related disorders. Founded as LQT Therapeutics, the company adopted the Thryv name in 2022.

Amplitude co-founder and managing partner with prior life-sciences investment leadership at BDC Capital and CDPQ and experience founding biotechnology companies.

Feldan Therapeutics board member and chair and chief executive of Thryv Therapeutics, identified in the current Feldan biography. Earlier founded and led Anthera Pharmaceuticals and Peninsula Pharmaceuticals. His education includes an MBA from Indiana University and an economics degree from the University of Waterloo.

Biopharmaceutical research and development leader and CTI Life Sciences Fund managing partner; serves on Aeovian Pharmaceuticals’ board.

Develops personalized neuromodulation therapies, initially for focal drug-resistant epilepsy in children and adults. Its Biomarker Targeted Stimulation platform uses patient-specific brain signals to guide and adapt electrical stimulation. The investigational system builds on research from Mayo Clinic and combines established stimulation hardware with new software.

Develops peripheral nerve stimulation systems for chronic neuropathic pain. Its investigational platform combines electrical stimulation with physiological sensing to personalize therapy, using implantable leads to record nerve-response biomarkers. The devices are engineered for movement, with a focus on wearability, lead stability and durability.

Neurologist and Head of Medical at Clene, concurrently Vice Chair of Clinical and Translational Research in neurology at UT Southwestern. His work includes multiple sclerosis and rare neurological disorders; he also advises Arialys Therapeutics.

Arialys Therapeutics is a La Jolla, California clinical-stage biotechnology company developing precision medicines for autoimmune neuropsychiatric disorders. It combines structural biology, receptor pharmacology and sensitive autoantibody detection to identify and block pathogenic antibodies in the central nervous system. Its lead investigational candidate ART5803 is a humanized monovalent monoclonal antibody designed to inhibit NMDA receptor autoantibodies in anti-NMDA receptor encephalitis and related autoimmune psychosis. Following healthy-volunteer Phase 1 studies, the company reported patient dosing in a Korean open-label Phase 2a study and FDA clearance for a separate randomized US Phase 2 study in June 2026. Arialys was founded by Avalon BioVentures, Catalys Pacific and MPM BioImpact, and purchased ART5803 from Astellas Pharma. The therapy remains investigational; trial clearance and regulatory designations do not establish approved efficacy.

Nadiya Ishnazarova is a TRIMTECH non-executive director and senior venture investor at Johnson & Johnson Innovation–JJDC. She previously invested in biotechnology at M Ventures and advised healthcare clients at Oliver Wyman. She holds an Oxford biochemistry doctorate and earlier chemistry and biotechnology qualifications from Moscow State University.

Johnson & Johnson Innovation–JJDC venture investor focused on new company creation. TRexBio director as of October 5, 2026, with resignation planned before IPO registration effectiveness; previously worked at Quaker Partners and in J&J research, operations and venture creation.

Johnson & Johnson Innovation – JJDC, Inc. is Johnson & Johnson’s corporate venture capital organization. It invests across company stages in biotechnology and medical technology, providing financing, company-building support and access to the parent group’s scientific and commercial capabilities. Its biotech focus includes neuropsychiatry, neurodegeneration, ophthalmology, oncology and immunology. Its MedTech focus spans neurovascular care, surgical technologies, digital systems and robotics, orthopaedics and vision. Its published holdings include neurodegenerative gene therapy developer AviadoBio, brain autoantibody therapeutics developer Arialys, targeted protein degrader company Prazer and AI cancer testing platform Artera. JJDC is the specific corporate venture capital entity, distinct from Johnson & Johnson Innovation’s broader partnering and JLABS incubation activities.